Dear AuntMinnie member,
In this edition of our Molecular Imaging Insider, we’ve highlighted secondary results from the LUNAR trial, with findings suggesting the benefits of lutetium-177 (Lu-177) PNT2002 before stereotactic body radiation therapy (SBRT) extend to more clinically meaningful disease states in men with prostate cancer. Click here for the details.
In other Lu-177-based radiopharmaceutical therapy developments, we noted that Novartis secured expanded approval in the U.S. for the use of Pluvicto, with the label update potentially doubling the number of eligible patients.
There’s no doubt that prostate cancer is among the hottest areas of research in the field, with PET scans leading the way. For instance, check out these stories we posted:
PSMA-PET/CT detected prostate cancer recurrence with higher sensitivity than multiparametric MRI after focal therapy.
A PET/MRI study found that androgen deprivation therapy used to treat prostate cancer causes progressive arterial inflammation.
A study showed that biopsies guided by PSMA-PET/CT detected more prostate cancer than standard systematic biopsies in men with negative MRI scans.
Cleveland Clinic researchers showed that PSMA-PET imaging combined with low-dose-rate brachytherapy can effectively treat locally recurrent prostate cancer.
But PET imaging is showing its stripes in other areas of cancer as well. In a study published in the Journal of Nuclear Medicine, researchers suggested that PET/CT scans can identify which patients with HER2-positive breast cancer will achieve complete responses to neoadjuvant therapy. Also, an experimental CAIX-targeted PET tracer called Ga-68 DPI-4452 achieved 100% sensitivity in detecting clear cell renal cell carcinoma.
Meanwhile, studies using fibroblast activation protein inhibitor (FAPI) PET radiotracers continue to show positive results, most recently for detecting hepatopancreatobiliary cancers.
Will Morton
Associate Editor
AuntMinnie.com
